NASDAQ:IMRN

Immuron Q1 2026 Earnings Results & Report

Immuron logo
$0.90 +0.05 (+5.86%)
Closing price 11/20/2026 03:49 PM Eastern
Extended Trading
$0.83 -0.07 (-7.54%)
As of 11/20/2026 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immuron reported Q1 2026 earnings on April 30, 2026. The company reported EPS of -$0.0950, while revenue was $1.40 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Immuron EPS Results

Actual EPS
-$0.0950
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Immuron Revenue Results

Actual Revenue
$1.40 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Immuron Q1 2026 Earnings FAQ

Immuron (NASDAQ:IMRN) reported earnings of -$0.0950 per share for Q1 2026. The report was announced on Thursday, April 30, 2026.

Immuron reported revenue of $1.40 million for Q1 2026.

Immuron Earnings Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
See More Immuron Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immuron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuron and other key companies, straight to your email.

About Immuron

Immuron (NASDAQ:IMRN) Limited is an Australian biopharmaceutical company that develops and commercializes oral antibody-based products. Its approach uses targeted antibodies intended to bind pathogens or other biological targets in the gastrointestinal tract.

The company’s principal commercial product is Travelan, an oral product designed to help prevent travelers’ diarrhea. Immuron also develops investigational therapies for infectious and inflammatory conditions, including candidates focused on Clostridioides difficile infection and other gastrointestinal diseases.

Based in Melbourne, Immuron serves customers in Australia and other markets through sales and distribution arrangements. Its activities span commercializing oral health products and advancing its therapeutic candidates through clinical development.

View Immuron Profile